{"result": {"id": "b373720e-c986-48cc-872c-bc5b9ba4df27", "choices": [{"finish_reason": "length", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>TARGET BP I<|>EVENT<|>A randomized clinical trial investigating the effect of alcohol-mediated renal denervation on blood pressure in the presence of antihypertensive medications, published in Circulation in 2024.\")\n##\n(\"entity\"<|>CIRCULATION<|>ORGANIZATION<|>A medical journal that published the TARGET BP I randomized clinical trial results.\")\n##\n(\"entity\"<|>KALARUS Z<|>PERSON<|>One of the authors of a pilot study on pacemaker-based cardiac neuromodulation therapy in patients with hypertension, published in JAm HeartAssoc in 2021.\")\n##\n(\"entity\"<|>MERKELY B<|>PERSON<|>One of the authors of a pilot study on pacemaker-based cardiac neuromodulation therapy in patients with hypertension, published in JAm HeartAssoc in 2021.\")\n##\n(\"entity\"<|>NEU?IL P<|>PERSON<|>One of the authors of a pilot study on pacemaker-based cardiac neuromodulation therapy in patients with hypertension, published in JAm HeartAssoc in 2021.\")\n##\n(\"entity\"<|>JAM HEARTASSOC<|>ORGANIZATION<|>A medical journal that published the pilot study on pacemaker-based cardiac neuromodulation therapy in patients with hypertension.\")\n##\n(\"entity\"<|>BOLIGNANO D<|>PERSON<|>One of the authors of a review on baroreflex stimulation for treating resistant hypertension, published in Rev CardiovascMed in 2018.\")\n##\n(\"entity\"<|>COPPOLINO G<|>PERSON<|>One of the authors of a review on baroreflex stimulation for treating resistant hypertension, published in Rev CardiovascMed in 2018.\")\n##\n(\"entity\"<|>REV CARDIOVASCMED<|>ORGANIZATION<|>A medical journal that published the review on baroreflex stimulation for treating resistant hypertension.\")\n##\n(\"entity\"<|>AMBARD L<|>PERSON<|>One of the authors of a study on the causes of arterial hypertension, published in Arch Gen Med in 1904.\")\n##\n(\"entity\"<|>BEAUCHARD E<|>PERSON<|>One of the authors of a study on the causes of arterial hypertension, published in Arch Gen Med in 1904.\")\n##\n(\"entity\"<|>ARCH GEN MED<|>ORGANIZATION<|>A medical journal that published the study on the causes of arterial hypertension in 1904.\")\n##\n(\"entity\"<|>徐湘茹<|>PERSON<|>One of the authors of a study on a modern diagnostic model for hypertension based on multimodal data, published in 世界科学技术-中医药现代化 in 2021.\")\n##\n(\"entity\"<|>何云<|>PERSON<|>One of the authors of a study on a modern diagnostic model for hypertension based on multimodal data, published in 世界科学技术-中医药现代化 in 2021.\")\n##\n(\"entity\"<|>周颖<|>PERSON<|>One of the authors of a study on a modern diagnostic model for hypertension based on multimodal data, published in 世界科学技术-中医药现代化 in 2021.\")\n##\n(\"entity\"<|>世界科学技术-中医药现代化<|>ORGANIZATION<|>A journal that published the study on a modern diagnostic model for hypertension based on multimodal data.\")\n##\n(\"entity\"<|>刘力生<|>PERSON<|>One of the authors of a study on 40 years of hypertension research, published in 中国医学科学院学报 in 2002.\")\n##\n(\"entity\"<|>陈孟勤<|>PERSON<|>One of the authors of a study on 40 years of hypertension research, published in 中国医学科学院学报 in 2002.\")\n##\n(\"entity\"<|>曾贵云<|>PERSON<|>One of the authors of a study on 40 years of hypertension research, published in 中国医学科学院学报 in 2002.\")\n##\n(\"entity\"<|>中国医学科学院学报<|>ORGANIZATION<|>A journal that published the study on 40 years of hypertension research.\")\n##\n(\"entity\"<|>ZHANG DY<|>PERSON<|>One of the authors of a randomized, placebo-controlled trial on the treatment of masked hypertension with a Chinese herbal formula, published in Circulation in 2020.\")\n##\n(\"entity\"<|>CHENG YB<|>PERSON<|>One of the authors of a randomized, placebo-controlled trial on the treatment of masked hypertension with a Chinese herbal formula, published in Circulation in 2020.\")\n##\n(\"entity\"<|>GUO QH<|>PERSON<|>One of the authors of a randomized, placebo-controlled trial on the treatment of masked hypertension with a Chinese herbal formula, published in Circulation in 2020.\")\n##\n(\"entity\"<|>刘梦琳<|>PERSON<|>One of the authors of a systematic review and trial sequential analysis on the treatment of primary hypertension with Tianma Gouteng Granules combined with antihypertensive drugs, published in 中国中药杂志 in 2021.\")\n##\n(\"entity\"<|>樊根豪<|>PERSON<|>One of the authors of a systematic review and trial sequential analysis on the treatment of primary hypertension with Tianma Gouteng Granules combined with antihypertensive drugs, published in 中国中药杂志 in 2021.\")\n##\n(\"entity\"<|>张怀亮<|>PERSON<|>One of the authors of a systematic review and trial sequential analysis on the treatment of primary hypertension with Tianma Gouteng Granules combined with antihypertensive drugs, published in 中国中药杂志 in 2021.\")\n##\n(\"entity\"<|>中国中药杂志<|>ORGANIZATION<|>A journal that published the systematic review and trial sequential analysis on the treatment of primary hypertension with Tianma Gouteng Granules combined with antihypertensive drugs.\")\n##\n(\"entity\"<|>LAI X<|>PERSON<|>One of the authors of a randomized, multicenter, double-blind, noninferiority trial comparing Chinese herbal medicine with losartan for mild essential hypertension, published in CircCardiovascQualOutcomes in 2022.\")\n##\n(\"entity\"<|>DONG Z<|>PERSON<|>One of the authors of a randomized, multicenter, double-blind, noninferiority trial comparing Chinese herbal medicine with losartan for mild essential hypertension, published in CircCardiovascQualOutcomes in 2022.\")\n##\n(\"entity\"<|>WU S<|>PERSON<|>One of the authors of a randomized, multicenter, double-blind, noninferiority trial comparing Chinese herbal medicine with losartan for mild essential hypertension, published in CircCardiovascQualOutcomes in 2022.\")\n##\n(\"entity\"<|>CIRCCARDIOVASCQUALOUTCOMES<|>ORGANIZATION<|>A medical journal that published the randomized trial comparing Chinese herbal medicine with losartan for mild essential hypertension.\")\n##\n(\"entity\"<|>樊根豪<|>PERSON<|>One of the authors of a systematic review on the effectiveness and safety of Songling Xuemaikang Capsule in treating primary hypertension, published in 中国中药杂志 in 2021.\")\n##\n(\"entity\"<|>邢作英<|>PERSON<|>One of the authors of a systematic review on the effectiveness and safety of Songling Xuemaikang Capsule in treating primary hypertension, published in 中国中药杂志 in 2021.\")\n##\n(\"entity\"<|>刘梦琳<|>PERSON<|>One of the authors of a systematic review on the effectiveness and safety of Songling Xuemaikang Capsule in treating primary hypertension, published in 中国中药杂志 in 2021.\")\n##\n(\"entity\"<|>WANG J<|>PERSON<|>One of the authors of a study on the effectiveness of Yangxue Qingnao Granule combined with antihypertensive drugs in treating essential hypertension, published in EvidBased Complement AlternatMed in 2013.\")\n##\n(\"entity\"<|>YANG X<|>PERSON<|>One of the authors of a study on the effectiveness of Yangxue Qingnao Granule combined with antihypertensive drugs in treating essential hypertension, published in EvidBased Complement AlternatMed in 2013.\")\n##\n(\"entity\"<|>FENG B<|>PERSON<|>One of the authors of a study on the effectiveness of Yangxue Qingnao Granule combined with antihypertensive drugs in treating essential hypertension, published in EvidBased Complement AlternatMed in 2013.\")\n##\n(\"entity\"<|>EVIDBASED COMPLEMENT ALTERNATMED<|>ORGANIZATION<|>A journal that published the study on the effectiveness of Yangxue Qingnao Granule combined with antihypertensive drugs in treating essential hypertension.\")\n##\n(\"entity\"<|>寇秋爱<|>PERSON<|>One of the authors of a clinical observation on the treatment of hypertension with Zhongfu Jiangya Capsule, published in 中国中西医结合杂志 in 2007.\")\n##\n(\"entity\"<|>于华萍<|>PERSON<|>One of the authors of a clinical observation on the treatment of hypertension with Zhongfu Jiangya Capsule, published in 中国中西医结合杂志 in 2007.\")\n##\n(\"entity\"<|>周国栋<|>PERSON<|>One of the authors of a clinical observation on the treatment of hypertension with Zhongfu Jiangya Capsule, published in 中国中西医结合杂志 in 2007.\")\n##\n(\"entity\"<|>中国中西医结合杂志<|>ORGANIZATION<|>A journal that published the clinical observation on the treatment of hypertension with Zhongfu Jiangya Capsule.\")\n##\n(\"entity\"<|>罗显云<|>PERSON<|>One of the authors of a randomized parallel controlled study on the treatment of primary hypertension with Xinmaitong Capsule combined with fosinopril, published in 实用中医内科杂志 in 2013.\")\n##\n(\"entity\"<|>姚震<|>PERSON<|>One of the authors of a randomized parallel controlled study on the treatment of primary hypertension with Xinmaitong Capsule combined with fosinopril, published in 实用中医内科杂志 in 2013.\")\n##\n(\"entity\"<|>张云波<|>PERSON<|>One of the authors of a randomized parallel controlled study on the treatment of primary hypertension with Xinmaitong Capsule combined with fosinopril, published in 实用中医内科杂志 in 2013.\")\n##\n(\"entity\"<|>实用中医内科杂志<|>ORGANIZATION<|>A journal that published the randomized parallel controlled study on the treatment of primary hypertension with Xinmaitong Capsule combined with fosinopril.\")\n##\n(\"entity\"<|>FLACHSKAMPF FA<|>PERSON<|>One of the authors of a randomized trial on acupuncture to lower blood pressure, published in Circulation in 2007.\")\n##\n(\"entity\"<|>GALLASCH J<|>PERSON<|>One of the authors of a randomized trial on acupuncture to lower blood pressure, published in Circulation in 2007.\")\n##\n(\"entity\"<|>GEFELLER O<|>PERSON<|>One of the authors of a randomized trial on acupuncture to lower blood pressure, published in Circulation in 2007.\")\n##\n(\"entity\"<|>JIAO HC<|>PERSON<|>One of the authors of a systematic review and meta-analysis on the efficacy of Chinese herbal medicine on health-related quality of life in hypertensive patients, published in ComplementTherMed in 2015.\")\n##\n(\"entity\"<|>JU JQ<|>PERSON<|>One of the authors of a systematic review and meta-analysis on the efficacy of Chinese herbal medicine on health-related quality of life in hypertensive patients, published in ComplementTherMed in 2015.\")\n##\n(\"entity\"<|>LI YL<|>PERSON<|>One of the authors of a systematic review and meta-analysis on the efficacy of Chinese herbal medicine on health-related quality of life in hypertensive patients, published in ComplementTherMed in 2015.\")\n##\n(\"entity\"<|>COMPLEMENTTHERMED<|>ORGANIZATION<|>A journal that published the systematic review and meta-analysis on the efficacy of Chinese herbal medicine on health-related quality of life in hypertensive patients.\")\n##\n(\"entity\"<|>ZHANG SF<|>PERSON<|>One of the authors of a study on Qian Yang Yu Yin Granule's protective effect against hypertension-induced renal injury, published in J Ethnopharmacol.\")\n##\n(\"entity\"<|>MAO XJ<|>PERSON<|>One of the authors of a study on Qian Yang Yu Yin Granule's protective effect against hypertension-induced renal injury, published in J Ethnopharmacol.\")\n##\n(\"entity\"<|>JIANG WM<|>PERSON<|>One of the authors of a study on Qian Yang Yu Yin Granule's protective effect against hypertension-induced renal injury, published in J Ethnopharmacol.\")\n##\n(\"entity\"<|>J ETHNOPHARMACOL<|>ORGANIZATION<|>A journal that published the study on Qian Yang Yu Yin Granule's protective effect against hypertension-induced renal injury.\")\n##\n(\"relationship\"<|>TARGET BP I<|>CIRCULATION<|>The TARGET BP I randomized clinical trial was published in Circulation.<|>8\")\n##\n(\"relationship\"<|>KALARUS Z<|>JAM HEARTASSOC<|>Kalarus Z is one of the authors of a study published in JAm HeartAssoc.<|>7\")\n##\n(\"relationship\"<|>MERKELY B<|>JAM HEARTASSOC<|>Merkely B is one of the authors of a study published in JAm HeartAssoc.<|>7\")\n##\n(\"relationship\"<|>NEU?IL P<|>JAM HEARTASSOC<|>Neu?il P is one of the authors of a study published in JAm HeartAssoc.<|>7\")\n##\n(\"relationship\"<|>BOLIGNANO D<|>REV CARDIOVASCMED<|>Bolignano D is one of the authors of a study published in Rev CardiovascMed.<|>7\")\n##\n(\"relationship\"<|>COPPOLINO G<|>REV CARDIOVASCMED<|>Coppolino G is one of the authors of a study published in Rev CardiovascMed.<|>7\")\n##\n(\"relationship\"<|>AMBARD L<|>ARCH GEN MED<|>Ambard L is one of the authors of a study published in Arch Gen Med.<|>7\")\n##\n(\"relationship\"<|>BEAUCHARD E<|>ARCH GEN MED<|>Beauchard E is one of the authors of a study published in Arch Gen Med.<|>7\")\n##\n(\"relationship\"<|>徐湘茹<|>世界科学技术-中医药现代化<|>徐湘茹 is one of the authors of a study published in 世界科学技术-中医药现代化.<|>7\")\n##\n(\"relationship\"<|>何云<|>世界科学技术-中医药现代化<|>何云 is one of the authors of a study published in 世界科学技术-中医药现代化.<|>7\")\n##\n(\"relationship\"<|>周颖<|>世界科学技术-中医药现代化<|>周颖 is one of the authors of a study published in 世界科学技术-中医药现代化.<|>7\")\n##\n(\"relationship\"<|>刘力生<|>中国医学科学院学报<|>刘力生 is one of the authors of a study published in 中国医学科学院学报.<|>7\")\n##\n(\"relationship\"<|>陈孟勤<|>中国医学科学院学报<|>陈孟勤 is one of the authors of a study published in 中国医学科学院学报.<|>7\")\n##\n(\"relationship\"<|>曾贵云<|>中国医学科学院学报<|>曾贵云 is one of the authors of a study published in 中国医学科学院学报.<|>7\")\n##\n(\"relationship\"<|>ZHANG DY<|>CIRCULATION<|>Zhang DY is one of the authors of a study published in Circulation.<|>7\")\n##\n(\"relationship\"<|>CHENG YB<|>CIRCULATION<|>Cheng YB is one of the authors of a study published in Circulation.<|>7\")\n##\n(\"relationship\"<|>GUO QH<|>CIRCULATION<|>Guo QH is one of the authors of a study published in Circulation.<|>7\")\n##\n(\"relationship\"<|>刘梦琳<|>中国中药杂志<|>刘梦琳 is one of the authors of a study published in 中国中药杂志.<|>7\")\n##\n(\"relationship\"<|>樊根豪<|>中国中药杂志<|>樊根豪 is one of the authors of a study published in 中国中药杂志.<|>7\")\n##\n(\"relationship\"<|>张怀亮<|>中国中药杂志<|>张怀亮 is one of the authors of a study published in 中国中药杂志.<|>7\")\n##\n(\"relationship\"<|>LAI X<|>CIRCCARDIOVASCQUALOUTCOMES<|>Lai X is one of the authors of a study published in CircCardiovascQualOutcomes.<|>7\")\n##\n(\"relationship\"<|>DONG Z<|>CIRCCARDIOVASCQUALOUTCOMES<|>Dong Z is one of the authors of a study published in CircCardiovascQualOutcomes.<|>7\")\n##\n(\"relationship\"<|>WU S<|>CIRCCARDIOVASCQUALOUTCOMES<|>Wu S is one of the authors of a study published in CircCardiovascQualOutcomes.<|>7\")\n##\n(\"relationship\"<|>樊根豪<|>中国中药杂志<|>樊根豪 is one of the authors of a study published in 中国中药杂志.<|>7\")\n##\n(\"relationship\"<|>邢作英<|>中国中药杂志<|>邢作英 is one of the authors of a study published in 中国中药杂志.<|>7\")\n##\n(\"relationship\"", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558922, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 4000, "prompt_tokens": 2757, "total_tokens": 6757, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 965}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: et al.  Effect of alcohol- mediated renaldenervation on blood pressure in the presence of antihypertensive  medications:    primary   results   from    the TARGET BP Ⅰ randomized clinicaltrial[J]. Circulation, 2024,  149(24) :1875-1884.\n[320]  KalarusZ, MerkelyB, Neu?ilP, etal. Pacemaker-basedcardiac\n\n\nneuromodulation therapy in patients with hypertension: a pilot study[J]. JAm HeartAssoc,2021,10(16) :e020492.\n[321]  BolignanoD,  Coppolino G.  Baroreflex stimulation for treating resistanthypertension: readyfortheprime-time?  [J]. Rev Car- diovascMed,2018,19(3) :89-95.\n[322]  AmbardL, BeauchardE.  Causes de l’hypertension arterielle [J]. Arch Gen Med,1904,1:520-533.\n[323]  徐湘茹 ,何云 ,周颖 ,等.  基于多模态的高血压阴虚证现代化诊断  模式初探[J]. 世界科学技术-中医药现代化 ,2021,23(11) :3926- 3931.\n[324]  刘力生 ,陈孟勤 , 曾贵云 ,等.  高血压研究四十年[J]. 中国医学科 学院学报 ,2002,24(4) :401-408.\n[325]  Zhang DY, Cheng YB, Guo QH, et al.  Treatmentofmasked hypertension with aChineseherbalformula: arandomized, pla- cebo-controlledtrial[J]. Circulation,2020,142(19) :1821-1830.\n[326]  刘梦琳 ,樊根豪 ,张怀亮.  天麻钩藤颗粒联合降压药治疗原发性 高血压病的系统评价及试验序贯分析[J]. 中国中药杂志 ,2021, 46(6) :1511-1522.\n[327]  LaiX, Dong Z, Wu S,  et al.  Efficacy and safety of Chinese herbalmedicinecomparedwithlosartanformildessentialhyper- tension: arandomized, multicenter, double-blind, noninferiority trial[J]. CircCardiovascQualOutcomes,2022,15(3) :e007923.\n[328]  樊根豪,邢作英 ,刘梦琳 ,等.  松龄血脉康胶囊治疗原发性高血压 病有效性及安全性的系统评价[J]. 中国中药杂志 ,2021,46(2) : 467-477.\n[329]  WangJ, Yang X, Feng B, et al.  Is YangxueQingnao granule combined with antihypertensive drugs, a new integrative medi- cinetherapy, moreeffectivethan antihypertensivetherapyalone in treating essentialhypertension?  [J]. EvidBased Complement AlternatMed,2013,2013:540613.\n[330]  寇秋爱 ,于华萍 ,周国栋 ,等.  中孚降压胶囊治疗高血压病阴虚阳 亢证临床观察[J]. 中国中西医结合杂志 ,2007,27(8) :745-748.\n[331]  罗显云 ,姚震 ,张云波 ,等.  心脉通胶囊联合福辛普利治疗原发性 高血压随机平行对照研究[J]. 实用中医内科杂志 ,2013,27(4) : 11-13.\n[332]  FlachskampfFA, GallaschJ, GefellerO, etal. Randomizedtri- alofacupunctureto lowerblood pressure[J]. Circulation,2007,  115(24) :3121-3129.\n[333] Jiao HC, JuJQ, LiYL, etal. EfficacyofChineseherbalmedi- cineon health-relatedqualityoflife(SF-36) in hypertensivepa- tients: asystematicreview andmeta-analysisofrandomizedcon- trolledtrials[J]. ComplementTherMed,2015,23(3) :494-504.\n[334]  ZhangSF, MaoXJ, JiangWM, etal. QianYangYuYinGran- uleprotects againsthypertension-induced renalinjury by epige- netic mechanism  linked  to nicotinamide N-methyltransferase (NNMT) expression[J]. J Ethnopharmacol,202\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_9cd483da83f6890a76051332fb97d16d3501c8ec5bc1e138ae83bc0e32aa6441_v2"}